Related references
Note: Only part of the references are listed.Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis
Yu Zhang et al.
INFLAMMATION RESEARCH (2021)
New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis
Mingyao Sun et al.
PHARMACOLOGICAL RESEARCH (2021)
The Diabetic Cardiac Fibroblast: Mechanisms Underlying Phenotype and Function
Scott P. Levick et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis
Sushweta Mahalanobish et al.
PHARMACOLOGICAL RESEARCH (2020)
Protein Kinase C delta (PKC delta) Attenuates Bleomycin Induced Pulmonary Fibrosis via Inhibiting NF-kappa B Signaling Pathway
Jun Wang et al.
FRONTIERS IN PHYSIOLOGY (2020)
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
Jun Jacob Hu et al.
NATURE IMMUNOLOGY (2020)
Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis
Qing Liang et al.
PHARMACOLOGICAL RESEARCH (2020)
Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence
Alberto Aimo et al.
PHARMACOLOGICAL RESEARCH (2020)
Fibroblasts in atherosclerosis: heterogeneous and plastic participants
Renee J. H. A. Tillie et al.
CURRENT OPINION IN LIPIDOLOGY (2020)
Redox Imbalance in Idiopathic Pulmonary Fibrosis: A Role for Oxidant Cross-Talk Between NADPH Oxidase Enzymes and Mitochondria
Carmen Veith et al.
ANTIOXIDANTS & REDOX SIGNALING (2019)
Lung transplantation for idiopathic pulmonary fibrosis
Peter M. George et al.
LANCET RESPIRATORY MEDICINE (2019)
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
Bruno Crestani et al.
LANCET RESPIRATORY MEDICINE (2019)
Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib
Gali Epstein Shochet et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2019)
Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases
Kenneth B. Liegner
ANTIBIOTICS-BASEL (2019)
Isolation and Long-term Cultivation of Mouse Alveolar Macrophages
Clara Jana-Lui Busch et al.
BIO-PROTOCOL (2019)
SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice
Juanjuan Shou et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Hydrophobic patches on SMAD2 and SMAD3 determine selective binding to cofactors
Ken-ichi Miyazono et al.
SCIENCE SIGNALING (2018)
Hydrophobic patches on SMAD2 and SMAD3 determine selective binding to cofactors
Ken-ichi Miyazono et al.
SCIENCE SIGNALING (2018)
Extracellular matrix regulation of fibroblast function: redefining our perspective on skin aging
Megan A. Cole et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2018)
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
Martin Kolb et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Shaney L. Barratt et al.
JOURNAL OF CLINICAL MEDICINE (2018)
The Role of TGF- Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
Akira Saito et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
AKT2 Regulates Pulmonary Inflammation and Fibrosis via Modulating Macrophage Activation
Yunjuan Nie et al.
JOURNAL OF IMMUNOLOGY (2017)
Selective Hydrogen Isotope Separation via Breathing Transition in MIL-53(AI)
Jin Yeong Kim et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Zdenek Skrott et al.
NATURE (2017)
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
Steven D. Nathan et al.
LANCET RESPIRATORY MEDICINE (2017)
Identification of a transitional fibroblast function in very early rheumatoid arthritis
Andrew Filer et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
SIRT1 regulates macrophage self-renewal
Francesco Imperatore et al.
EMBO JOURNAL (2017)
A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone
Larissa Knueppel et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2017)
Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring
Sarah D. Ahadome et al.
JCI INSIGHT (2016)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Nintedanib in the treatment of idiopathic pulmonary fibrosis
Mariano E. Mazzei et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2015)
High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells
Parvinder Hothi et al.
Oncotarget (2015)
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Vincent Cottin et al.
EUROPEAN RESPIRATORY REVIEW (2015)
Future Directions in Idiopathic Pulmonary Fibrosis Research
Timothy S. Blackwell et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Copper Signaling Axis as a Target for Prostate Cancer Therapeutics
Rachid Safi et al.
CANCER RESEARCH (2014)
Fibrosis in Ulcerative Colitis: Mechanisms, Features, and Consequences of a Neglected Problem
Ilyssa O. Gordon et al.
INFLAMMATORY BOWEL DISEASES (2014)
Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-κB pathway inhibition
Jie Zha et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature
Kristin D. Kistler et al.
BMC PULMONARY MEDICINE (2014)
Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis
Lutz Wollin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Katrin E. Hostettler et al.
RESPIRATORY RESEARCH (2014)
A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Richard E. Kast et al.
ONCOTARGET (2013)
Abnormal Lung Aging in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
Rosa Faner et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties
N. C. Yip et al.
BRITISH JOURNAL OF CANCER (2011)
Idiopathic pulmonary fibrosis
Talmadge E. King et al.
LANCET (2011)
Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction
Dmitri V. Pechkovsky et al.
CLINICAL IMMUNOLOGY (2010)
Blockade of Endothelial-Mesenchymal Transition by a Smad3 Inhibitor Delays the Early Development of Streptozotocin-Induced Diabetic Nephropathy
Jinhua Li et al.
DIABETES (2010)
Pirfenidone in idiopathic pulmonary fibrosis
H. Taniguchi et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
The multifaceted role of pirfenidone and its novel targets
Jose Macias-Barragan et al.
FIBROGENESIS & TISSUE REPAIR (2010)
Disulfiram Reduces Elevated Blood Glucose Levels in Otsuka Long-Evans Tokushima Fatty (OLETF) Rats, a Model of Type 2 Diabetes
Noriaki Nagai et al.
JOURNAL OF OLEO SCIENCE (2009)
Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity
Di Chen et al.
CANCER RESEARCH (2006)
Transforming growth factor-β signaling through the Smad proteins:: Role in systemic sclerosis
Franck Verrecchia et al.
AUTOIMMUNITY REVIEWS (2006)
Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram
H Lövborg et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-β1-induced extracellular matrix expression
M Jinnin et al.
MOLECULAR PHARMACOLOGY (2006)
Effects of dopamine β-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice
BN Bourdélat-Parks et al.
PSYCHOPHARMACOLOGY (2005)
TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis
P Bonniaud et al.
JOURNAL OF IMMUNOLOGY (2005)
Disulfiram-mediated inhibition of NF-κB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines
WG Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts
TL McGaha et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2002)
Disulfiram is a potent in vitro inhibitor of DNA topoisomerases
JS Yakisich et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Share Paper
